These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26029896)

  • 1. Examining the potential role of a supervised injection facility in Saskatoon, Saskatchewan, to avert HIV among people who inject drugs.
    Jozaghi E; Jackson A
    Int J Health Policy Manag; 2015 Mar; 4(6):373-9. PubMed ID: 26029896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Ottawa, Canada.
    Jozaghi E; Reid AA; Andresen MA; Juneau A
    Subst Abuse Treat Prev Policy; 2014 Aug; 9():31. PubMed ID: 25091704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The projected costs and benefits of a supervised injection facility in Seattle, WA, USA.
    Hood JE; Behrends CN; Irwin A; Schackman BR; Chan D; Hartfield K; Hess J; Banta-Green C; Whiteside L; Finegood B; Duchin J
    Int J Drug Policy; 2019 May; 67():9-18. PubMed ID: 30802842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supervised injection facility use and all-cause mortality among people who inject drugs in Vancouver, Canada: A cohort study.
    Kennedy MC; Hayashi K; Milloy MJ; Wood E; Kerr T
    PLoS Med; 2019 Nov; 16(11):e1002964. PubMed ID: 31770391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada.
    Enns EA; Zaric GS; Strike CJ; Jairam JA; Kolla G; Bayoumi AM
    Addiction; 2016 Mar; 111(3):475-89. PubMed ID: 26616368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Vancouver Canada's supervised injection facility cost-saving?
    Pinkerton SD
    Addiction; 2010 Aug; 105(8):1429-36. PubMed ID: 20653622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility.
    Irwin A; Jozaghi E; Weir BW; Allen ST; Lindsay A; Sherman SG
    Harm Reduct J; 2017 May; 14(1):29. PubMed ID: 28532488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost-benefit and cost-effectiveness analysis of Vancouver's supervised injection facility.
    Andresen MA; Boyd N
    Int J Drug Policy; 2010 Jan; 21(1):70-6. PubMed ID: 19423324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of harm reduction.
    Wilson DP; Donald B; Shattock AJ; Wilson D; Fraser-Hurt N
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S5-11. PubMed ID: 25727260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of on-site detoxification services co-located with a supervised injection facility.
    Gaddis A; Kennedy MC; Nosova E; Milloy MJ; Hayashi K; Wood E; Kerr T
    J Subst Abuse Treat; 2017 Nov; 82():1-6. PubMed ID: 29021106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supervised injection facilities in Canada: past, present, and future.
    Kerr T; Mitra S; Kennedy MC; McNeil R
    Harm Reduct J; 2017 May; 14(1):28. PubMed ID: 28521829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of Vancouver's supervised injection facility.
    Bayoumi AM; Zaric GS
    CMAJ; 2008 Nov; 179(11):1143-51. PubMed ID: 19015565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How many HIV infections are prevented by Vancouver Canada's supervised injection facility?
    Pinkerton SD
    Int J Drug Policy; 2011 May; 22(3):179-83. PubMed ID: 21450450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perceptions about supervised injection facilities among people who inject drugs in Philadelphia.
    Harris RE; Richardson J; Frasso R; Anderson ED
    Int J Drug Policy; 2018 Feb; 52():56-61. PubMed ID: 29241143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the cost-effectiveness of needle-syringe programs in Australia.
    Kwon JA; Anderson J; Kerr CC; Thein HH; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP
    AIDS; 2012 Nov; 26(17):2201-10. PubMed ID: 22914579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of naloxone distribution alone or in combination with addiction treatment with or without pre-exposure prophylaxis for HIV prevention in people who inject drugs: a cost-effectiveness modelling study.
    Uyei J; Fiellin DA; Buchelli M; Rodriguez-Santana R; Braithwaite RS
    Lancet Public Health; 2017 Mar; 2(3):e133-e140. PubMed ID: 29253386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada.
    Jozaghi E; Reid AA; Andresen MA
    Subst Abuse Treat Prev Policy; 2013 Jul; 8():25. PubMed ID: 23837814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The willingness of people who inject drugs in Boston to use a supervised injection facility.
    León C; Cardoso L; Mackin S; Bock B; Gaeta JM
    Subst Abus; 2018 Jan; 39(1):95-101. PubMed ID: 28799847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acceptability of supervised injection facilities among persons who inject drugs in upstate New York.
    Duncan E; Shufelt S; Barranco M; Udo T
    Harm Reduct J; 2022 Jul; 19(1):87. PubMed ID: 35907854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Willingness to use a supervised injection facility among young adults who use prescription opioids non-medically: a cross-sectional study.
    Bouvier BA; Elston B; Hadland SE; Green TC; Marshall BD
    Harm Reduct J; 2017 Feb; 14(1):13. PubMed ID: 28219388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.